{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:14:44Z","timestamp":1790273684029,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008076","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T00:00:00Z","timestamp":1295395200000}}],"reference-count":35,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008076.pub2","type":"journal-article","created":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T00:53:31Z","timestamp":1294275211000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin"],"prefix":"10.1002","volume":"2011","author":[{"given":"Ayeesha K","family":"Kamal","sequence":"first","affiliation":[{"name":"Aga Khan University Hospital; Stroke Service, International Cerebrovascular Translational Clinical Research Training Program, Section of Neurology, Department of Medicine; Stadium Road PO Box 3500 Karachi Pakistan 74800"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imama","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital; Stroke Service, International Cerebrovascular Translational Clinical Research Training Program, Section of Neurology, Department of Medicine; Stadium Road PO Box 3500 Karachi Pakistan 74800"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad R","family":"Husain","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital; Stroke Service, Section of Neurology, Department of Medicine; Stadium Road PO Box 3500 Karachi Pakistan 74800"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhojo A","family":"Khealani","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital; Stroke Service, Section of Neurology, Department of Medicine; Stadium Road PO Box 3500 Karachi Pakistan 74800"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"key":"10.1002\/14651858.CD008076.pub2-BIB0002|cit1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurology"},{"issue":"8","key":"10.1002\/14651858.CD008076.pub2-BIB0001|cit2","first-page":"675","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1002\/14651858.CD008076.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2):an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-8227(00)00235-7","article-title":"Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus","volume":"52","author":"Ahn","year":"2001","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0005|cit5","unstructured":"Uchiyama S Sakai N Kimura Y Ezura M Okada Y Takagi M Cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS): current status Proceedings of the 18th European Stroke Conference 2009 Sweden, Stockholm"},{"issue":"4","key":"10.1002\/14651858.CD008076.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/jscd.2000.7216","article-title":"Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh","year":"2000","journal-title":"Journal of Stroke and Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2840-5-16","article-title":"Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: Study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)","volume":"5","author":"Yamasaki","year":"2006","journal-title":"Cardiovascular Diabetology"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0008|cit8","unstructured":"Lee KY Han SW Lee JY Kim GS Lee JH Kim OJ Study for the multi-centre placebo-controlled double-blind clinical trial for the evaluation of the effect of cilostazol on pulsatility index of transcranial doppler in the acute lacunar infarction patients Proceedings of the International Stroke Conference 2009 USA, San Diego, California"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0009|cit9","first-page":"563","article-title":"Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study","volume":"37","author":"Ikeda","year":"1987","journal-title":"Arzneimittel-Forschung"},{"issue":"8","key":"10.1002\/14651858.CD008076.pub2-BIB0010|cit10","first-page":"771","article-title":"Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase - assessment of its effect on coagulation and fibrinolytic parameters","volume":"34","author":"Kohriyama","year":"1994","journal-title":"Rinsho Shinkeigaku Clinical Neurology (Tokyo)"},{"issue":"6","key":"10.1002\/14651858.CD008076.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1507\/endocrj.51.545","article-title":"Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients","volume":"51","author":"Mitsuhashi","year":"2004","journal-title":"Endocrine Journal"},{"issue":"4","key":"10.1002\/14651858.CD008076.pub2-BIB0012|cit12","first-page":"e236 (Abst.129)","article-title":"Cilostazol improves outcome after subarachnoid hemorrhage","volume":"41","author":"Suzuki","year":"2010","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0013|cit13","first-page":"315","article-title":"Aspirin and cilostazol vs aspirin alone for the prevention of progressing stroke","volume":"3 Suppl 1","author":"Terayama","year":"2008","journal-title":"International Journal of Stroke"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.STR.0000157667.06542.b7","article-title":"Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis. The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis","volume":"36","author":"Cho","year":"2005","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD008076.pub2-BIB0015|cit15","first-page":"10-1 (Abst. 5)","article-title":"Trial of efficacy and safety of cilostazol on the progression of symptomatic intracranial stenosis comparing clopidogrel: trial of cilostazol in symptomatic intracranial stenosis-2 (TOSS-2)","volume":"27 Suppl 6","author":"Kwon","year":"2009","journal-title":"Cerebrovascular Diseases"},{"issue":"II 7a","key":"10.1002\/14651858.CD008076.pub2-BIB0016|cit16","first-page":"1186","article-title":"Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease","volume":"35","author":"Yasunaga","year":"1985","journal-title":"Arzneimittel-Forschung"},{"issue":"1","key":"10.1002\/14651858.CD008076.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/anr.1780320102","article-title":"The mechanisms of action of nonsteroidal antiinflammatory drugs","volume":"32","author":"Abramson","year":"1989","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD008076.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jnnp.60.2.197","article-title":"Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia","volume":"60","author":"Algra","year":"1996","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008076.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.STR.26.3.386","article-title":"Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study","volume":"26","author":"Burke","year":"1995","journal-title":"Stroke"},{"issue":"12","key":"10.1002\/14651858.CD008076.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/01.ATV.18.12.1942","article-title":"Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication","volume":"18","author":"Elam","year":"1998","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"10","key":"10.1002\/14651858.CD008076.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1212\/WNL.40.10.1540","article-title":"Chinese-white differences in the distribution of occlusive cerebrovascular disease","volume":"40","author":"Feldmann","year":"1990","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008076.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008076.pub2-BIB0023|cit23","first-page":"435","article-title":"Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor","volume":"82","author":"Ikeda","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD008076.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0049-3848(98)00172-8","article-title":"Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro","volume":"93","author":"Inoue","year":"1999","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1002\/14651858.CD008076.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1006\/bbrc.1997.7323","article-title":"The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells","volume":"238","author":"Kayanoki","year":"1997","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1002\/14651858.CD008076.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","article-title":"Inhibition of adenosine uptake and augmentation of ischaemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication","volume":"36","author":"Liu","year":"2000","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD008076.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1474-4422(07)70004-2","article-title":"Stroke in China: epidemiology, prevention, and management strategies","volume":"6","author":"Liu","year":"2007","journal-title":"Lancet Neurology"},{"issue":"9524","key":"10.1002\/14651858.CD008076.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","article-title":"Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data","volume":"367","author":"Lopez","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008076.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2005.09.003","article-title":"Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study","volume":"6","author":"Matsumoto","year":"2005","journal-title":"Atherosclerosis Supplements"},{"issue":"25","key":"10.1002\/14651858.CD008076.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0024-3205(97)00986-7","article-title":"Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo","volume":"61","author":"Minami","year":"1997","journal-title":"Life Sciences"},{"issue":"10","key":"10.1002\/14651858.CD008076.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1055\/s-2007-979086","article-title":"Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumour necrosis factor-alpha in vascular endothelial cells","volume":"29","author":"Nishio","year":"1997","journal-title":"Hormone and Metabolic Research"},{"issue":"3","key":"10.1002\/14651858.CD008076.pub2-BIB0032|cit32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003748.pub3","article-title":"Cilostazol for peripheral arterial disease","author":"Robless","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008076.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000120687","article-title":"Risk factor profile and management of cerebrovascular patients in the REACH Registry","volume":"25","author":"Rother","year":"2008","journal-title":"Cerebrovascular Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008076.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000135654","article-title":"Antiplatelet cilostazol is beneficial in diabetic and\/or hypertensive ischaemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study","volume":"26","author":"Shinohara","year":"2008","journal-title":"Cerebrovascular Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008076.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/hs0202.102602","article-title":"Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke","volume":"33","author":"Wong","year":"2002","journal-title":"Stroke"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008076.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:07:03Z","timestamp":1760314023000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008076.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Stroke Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,19]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008076.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,19]]}}}